title: Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables.
abstract: Tumoural angiogenesis is essential for the growth and spread of breast cancer cells. Therefore the aim of this study was to assess the diagnostic performance of angiogenesis markers in tumours and there reflecting levels in serum of breast cancer patients. Angiogenin, Ang2, fibroblast growth factor basic, intercellular adhesion molecule (ICAM)-1, keratinocyte growth factor (KGF), platelet-derived growth factor-BB, and VEGF-A were measured using a FASTQuant angiogenic growth factor multiplex protein assay. We observed that breast cancer tumours exhibited high levels of PDGF-BB, bFGF and VEGF, and extremely high levels of TIMP-1 and Ang-2, whereas in serum we found significantly higher levels of Ang-2, PDGF-BB, bFGF, ICAM-1 and VEGF in patients with breast cancer compared to the benign breast diseases patients. Moreover, some of these angiogenesis markers evaluated in tumour and serum of breast cancer patients exhibited association with standard clinical parameters, ER status as well as MVD of tumours. Angiogenesis markers play important roles in tumour growth, invasion and metastasis. Our results suggest that analysis of angiogenesis markers in tumour and serum of breast cancer patients using multiplex protein assay can improve diagnosis and prognosis in this diseases.
authors.affiliation: Department of Plastic, Reconstructive and Aesthetic Surgery, Barlicki Hospital, Medical University of Lodz, Kopcinskiego 22, 90-153, Lodz, Poland. janekrykalarykala@gmail.com
authors.forename: Jan
authors.initials: J
authors.lastname: Rykala
authors.forename: Karolina
authors.initials: K
authors.lastname: Przybylowska
authors.forename: Ireneusz
authors.initials: I
authors.lastname: Majsterek
authors.forename: Grazyna
authors.initials: G
authors.lastname: Pasz-Walczak
authors.forename: Andrzej
authors.initials: A
authors.lastname: Sygut
authors.forename: Adam
authors.initials: A
authors.lastname: Dziki
authors.forename: Julia
authors.initials: J
authors.lastname: Kruk-Jeromin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D042702:Angiopoietin-2 / Q000097:blood; D000077214:Becaplermin; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000098:blood supply* / Q000473:pathology*; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000097:blood; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000097:blood / Q000473:pathology; D011379:Prognosis; D020574:Proto-Oncogene Proteins c-sis / Q000097:blood; D012259:Ribonuclease, Pancreatic / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D042702:Angiopoietin-2; D014408:Biomarkers, Tumor; C496453:FGF7 protein, human; D020574:Proto-Oncogene Proteins c-sis; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051523:Fibroblast Growth Factor 7; D018799:Intercellular Adhesion Molecule-1; D000077214:Becaplermin; D005346:Fibroblast Growth Factors; C046366:angiogenin; D012259:Ribonuclease, Pancreatic